Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease.

Deli Wang¹, Hana Florian¹, Shau-Yu Lynch¹, Weining Robieson¹, Run Zhuang², Coco Kusiak², Jessica L Ross², Jonathan R Walsh², Ole Graff¹

¹ABBVIE INC. Chicago Illinois USA.

²Research and Development UNLEARN AI San Francisco California USA.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Machine learning models leverage baseline data to create artificial intelligence (AI)-generated digital twins (DTs)-individualized predictions of each participant's clinical outcomes if they had received placebo. Incorporating DTs may increase statistical power or reduce required sample sizes in Phase 2 or 3 trials, and therefore improve efficiency in Alzheimer's disease (AD) trials.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.